These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26384344)

  • 1. A novel retroviral mutagenesis screen identifies prognostic genes in RUNX1 mediated myeloid leukemogenesis.
    Rae DT; Hocum JD; Bii V; Deeg HJ; Trobridge GD
    Oncotarget; 2015 Oct; 6(31):30664-74. PubMed ID: 26384344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
    Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
    Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes.
    Harada Y; Inoue D; Ding Y; Imagawa J; Doki N; Matsui H; Yahata T; Matsushita H; Ando K; Sashida G; Iwama A; Kitamura T; Harada H
    Blood; 2013 Apr; 121(17):3434-46. PubMed ID: 23471304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
    Harada H
    Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
    [No Abstract]   [Full Text] [Related]  

  • 10. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.
    Satoh Y; Matsumura I; Tanaka H; Harada H; Harada Y; Matsui K; Shibata M; Mizuki M; Kanakura Y
    Leukemia; 2012 Feb; 26(2):303-11. PubMed ID: 21836608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
    Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
    Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
    Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
    Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H; Harada Y; Kimura A
    Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.
    Matsuura S; Komeno Y; Stevenson KE; Biggs JR; Lam K; Tang T; Lo MC; Cong X; Yan M; Neuberg DS; Zhang DE
    Blood; 2012 Nov; 120(19):4028-37. PubMed ID: 22919028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
    Babushok DV; Bessler M
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia.
    Foster N; Paulsson K; Sales M; Cunningham J; Groves M; O'Connor N; Begum S; Stubbs T; McMullan DJ; Griffiths M; Pratt N; Tauro S
    Br J Haematol; 2010 Mar; 148(6):938-43. PubMed ID: 20064152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial myelodysplasia and acute myeloid leukaemia--a review.
    Owen C; Barnett M; Fitzgibbon J
    Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.